CN1232289C - Medicine for treating cranial vascular disease - Google Patents
Medicine for treating cranial vascular disease Download PDFInfo
- Publication number
- CN1232289C CN1232289C CN 200410003026 CN200410003026A CN1232289C CN 1232289 C CN1232289 C CN 1232289C CN 200410003026 CN200410003026 CN 200410003026 CN 200410003026 A CN200410003026 A CN 200410003026A CN 1232289 C CN1232289 C CN 1232289C
- Authority
- CN
- China
- Prior art keywords
- medicine
- present
- herba ocimi
- wine
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 229940079593 drug Drugs 0.000 title description 9
- 208000019553 vascular disease Diseases 0.000 title 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 14
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 12
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 12
- 241000218628 Ginkgo Species 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 2
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 235000010676 Ocimum basilicum Nutrition 0.000 abstract 1
- 240000007926 Ocimum gratissimum Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000000341 volatile oil Substances 0.000 description 13
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 238000002481 ethanol extraction Methods 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 238000001556 precipitation Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004394 hip joint Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010048962 Brain oedema Diseases 0.000 description 3
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 208000006752 brain edema Diseases 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229960003699 evans blue Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004781 brain capillary Anatomy 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 210000001226 toe joint Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 235000019890 Amylum Nutrition 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention belongs to a medicine for treating cerebrovascular diseases, particularly to a medicine of a traditional Chinese medicine preparation for treating cerebrovascular diseases. The present invention discloses the medicine for treating cerebrovascular diseases which is prepared from ginkgo leaf 9 to 12, sweet basil herb 12 to 15, wine rhubarb 6 to 9 and Chuanxiong rhizome 9 to 12 according to a weight compounding ratio. The present invention is the medicine for treating cerebrovascular diseases of a traditional Chinese medicine preparation, which has the advantages of conspicuous curative effect and low cost.
Description
(1) described technical field
The invention belongs to a kind of medicine for the treatment of cerebrovascular disease, particularly a kind of medicine for the treatment of the Chinese medicine preparation of cerebrovascular disease.
(2) background technology
Cerebrovascular disease is a kind of commonly encountered diseases, frequently-occurring disease, and its patient's condition is anxious, disease is changeable, and sick rate height, sequela weigh, are with unexpected eye tiltedly, dysphonia, and hemiplegia, even unexpected dusk servant, syncope is a class disease of feature.Serious harm people's life and life quality, existing market lack specific treatment medicine and rehabilitation medicine.
(3) summary of the invention
The object of the present invention is to provide the medicine of the treatment cerebrovascular disease of pure Chinese medicinal preparation a kind of evident in efficacy, with low cost.
The object of the present invention is achieved like this:
The invention discloses a kind of medicine for the treatment of cerebrovascular disease, is to be made by following weight proportion raw material and pharmaceutically acceptable auxiliaries,
Folium Ginkgo 9～12 Herba Ocimi (Herba Ocimi Pilosi)s 12～15 Radix et Rhizoma Rhei (stir-fried with wine) 6-9
Rhizoma Chuanxiong 9～12.
Medicine of the present invention also can be made by following weight proportion raw material and pharmaceutically acceptable auxiliaries,
Folium Ginkgo 9～12 Herba Ocimi (Herba Ocimi Pilosi)s 12～15 Radix et Rhizoma Rhei (stir-fried with wine) 6-9
Rhizoma Chuanxiong 9～12 Borneolum Syntheticums 0.15～0.3.
Medicine of the present invention can be made capsule, granule, tablet and gel.1. medicine production technology of the present invention
1.1 the foundation of technological design and general thought
The design of this extraction process is that the characteristics according to the prescription Chinese medicine design, and total extracting method is divided into: two lifting manipulations, water extracting alcohol precipitation and ethanol extraction method.
1.2 two lifting manipulations
Contain the volatilization oil properties according to Herba Ocimi (Herba Ocimi Pilosi), Rhizoma Chuanxiong, adopt two lifting manipulations to extract.Determine that by orthogonal test extraction process is: water is pulverized, added to Herba Ocimi (Herba Ocimi Pilosi), Rhizoma Chuanxiong, adopts steam distillation to extract volatile oil 4-6 hour, collects volatile oil.
1.3 water is carried ethanol precipitation
Herba Ocimi (Herba Ocimi Pilosi), Rhizoma Chuanxiong extract the medicinal residues behind the volatile oil, decoct with water secondary, each 1-4 hour merging decoction liquor.Concentrate, add ethanol and make and contain the alcohol amount and be 70-90%, placement, filtration, collecting precipitation, filtrate recycling ethanol.
1.4 ethanol extraction
Folium Ginkgo, Radix et Rhizoma Rhei (stir-fried with wine) are pulverized, and add 60-90% ethanol extraction secondary, and each 1-4 hour, merge extractive liquid, filtered filtrate recycling ethanol.
1.5 moulding process
The preparation of gel: it is 1-6% that Ka Baimujia water is made into concentration, places mixing, hydro-oxidation sodium solution or triethanolamine 12-48 hour; Transfer PH6-8, placed 12-48 hour, add the 2-10% propylene glycol, the 1-5% azone gets substrate behind the mixing.Then, with volatile oil, water extract-alcohol precipitation extract, ethanol extraction, directly or being added to behind the dissolve with ethanol in the aforementioned substrate, mixing, packing is promptly.
The preparation of other dosage form: with volatile oil, water extract-alcohol precipitation extract, after alcohol extract mixes, add conventional pharmaceutically acceptable auxiliaries, make required dosage form with the preparation method of routine.
2. followingly be the pharmacodynamics test of medicine of the present invention
2.1 medicine of the present invention is to the influence of rat brain mantle blood flow
Animal is divided into 5 groups, and the large, medium and small dosage group of medicine of the present invention, modeling group, positive controls adopt brain common carotid artery ligation method, measures before the administration brain mantle blood flow of different time behind the animal brain mantle blood flow and administration respectively.
Conclusion: the large, medium and small dosage group of medicine of the present invention can both significantly increase the cerebral blood flow of rat, and illustrating has significant improvement to rat brain mantle blood flow.
2.2 medicine of the present invention is to the influence of rat brain edema
Behind the rat successive administration three days, 1h after the last administration, with the ligation of rat brain common carotid artery, sacrificed by decapitation behind the ligation 3h is opened cranium and is got brain, claims weight in wet base, calculates cerebral index, and oven dry claims dry weight then, calculates brain water content.
Conclusion: medicine of the present invention obviously reduces the rat brain edema.
2.3 medicine of the present invention is to the influence of rat brain capillary permeability
Behind the rat successive administration three days, 1h after the last administration, non-modeling group and modeling treated animal are by vena femoralis injection azovan blue 50mg/kg, 5 minutes ligation bilateral common carotid arteries behind the injection azovan blue are behind the ligation 3h, after broken end is got brain and weighed, put into Methanamide and hatch 72h, leachate in 620nm place photometry density, calculates the azovan blue seepage discharge with 751 spectrophotometers, observes the influence that medicine oozes out cerebrovascular.
Conclusion: medicine of the present invention can improve the permeability of rat brain blood capillary.
2.4 medicine of the present invention is to the influence of rats with cerebral ischemia brain morphology
Cerebral ischemic model rat successive administration is after 15 days, conventional fixing with rat brain, paraffin embedding film-making, HE dyeing, light microscopic and electron microscopic examination.
2.5 medicine of the present invention is to the influence of thrombosis
A) medicine is to thrombotic influence: use rat and observe medicine in the body and the influence that forms of external thrombus.
B) medicine thrombolytic test: observe the thrombolytic effect of medicine to thrombus in vivo.
Conclusion: by test as can be known, the large, medium and small dosage group of medicine of the present invention all can obviously prolong the thrombotic time, P＜0.01.And dosage increase effect strengthens, and illustrates that medicine of the present invention can suppress the formation of thrombosis.
2.6 medicine of the present invention is to hemorheological influence
Observe the influence of medicine to intact animal or animal pattern blood viscosity.
According to above pharmacodynamics test, can draw as drawing a conclusion: medicine of the present invention has significant improvement to rat brain mantle blood flow, can obviously reduce the rat brain edema, and improves the rat brain capillary permeability.Simultaneously, medicine of the present invention has tangible thrombolytic effect.
3. the toxicity test of medicine of the present invention
3.1 acute toxicity test
Medicine mice ig maximum dosage-feeding of the present invention is equivalent to 653 times of clinical consumptions.Observed 7 days behind the mouse stomach, do not see death and other abnormal phenomenas, body weight gain is normal, and appetite is good.Put to death after 7 days, the ANOMALOUS VARIATIONS of internal organs is not seen in perusal yet, and the overt toxicity reaction does not appear in mice, and it is safe pointing out clinical use.
3.2 long term toxicity test
Test method: get 160 of health rats in 5 age in week, ♀ ♂ half and half is divided into matched group, low amount group, middle dosage group, high dose group at random.Every treated animal gastric infusion, 6 days weekly, continuous 26 weeks.Administration finishes the back and continues to observe for 4 weeks.Every day, the general behavior of observation experiment animal showed, the appetite body weight of record animal.In 13 weeks of medication, 26 weeks and 30 when week blood drawings detect the hematology, blood biochemical is learned index, and in medication during 13 weeks every group put to death 10 animals at random, when 26 weeks, put to death 20 animals at random for every group, 30 weeks were put to death the residue animals.Animal is cutd open inspection, and taking internal organ is weighed and is carried out histopathological examination.Route of administration adopts administration by gavage with clinical consistent, and every morning is administered once, and administration is 6 days weekly, adjusts dosage every 7 days according to the weight increase situation, and each group usefulness waits not isoconcentration administration of capacity.
Result of the test: continuous 26 weeks of gastric infusion of medicine of the present invention, the overt toxicity reaction relevant that animal general behavior, appetite, hematology, blood biochemical are learned, histopathologic examination does not see with medicine medication of the present invention.Prove that it is safe that medicine of the present invention is taken for a long time.
4. followingly be the clinical trial of medicine of the present invention
Clinical experiment: diagnostic criteria, observation index, curative effect determinate standard and efficacy assessment standard are with reference to " Chinese medicine newly treat apoplexy clinical research direct study "
Experimental group 20 examples: take the capsule (Shandong Traditional Chinese Medicine University's experiment pharmaceutical factory system) that medicine of the present invention is made
Medicine is formed: Herba Ocimi (Herba Ocimi Pilosi), Folium Ginkgo, Rhizoma Chuanxiong, Radix et Rhizoma Rhei (stir-fried with wine)
Function cures mainly: invigorate blood circulation, blood stasis dispelling, collateral dredging, be mainly used in the convalescent period of cerebral thrombosis and the blood stasis resistance network card of sequela stage, card is seen dizziness, numb limbs and tense tendons, contracture of the limbs, half body not with etc.
Usage and dosage: every day 3 times, each 3, oral, 1 month was 1 course of treatment.
The clinical experiment result: be almost recovered 40%, produce effects 30%, effective 30%, patient's nervous system signs, motor function and language situation are obviously improved, and the patient reflects that generally the aftersensation of taking medicine is comfortable, does not see after taking medicine that the patient has bad reflection and side effect.
Model case: 1, Ma's sex: woman's age: 49 addresses: Zhou village, Zibo City
Concise and to the point medical history: the left limb numbness, in movable unfavorable January, have a medical check-up: left limb limb power III
+
Main symptom: upper limb articulations digitorum manus: clench fist and stretch finger (2 minutes), the lower limb hip joint: 45 ℃ of persons of less than (2 minutes)
Rheoencephalogram: diagnostic comments: 1, vertebra substrate A
sThe left side wave amplitude is lower than normally.
2, the both sides wave amplitude is asymmetric, amplitude differences＞and more than 25%
The hemorheology index: whole blood viscosity 4.99, plasma viscosity 1.93 waits an index to be higher than reference range.
After taking medicine 1 month, main symptom: upper limb refers to close: normal 0 minute, the lower limb hip joint: normal 0 minute, upper limb shoulder joint and language performance made moderate progress.
Rheoencephalogram: diagnostic comments: vertebra substrate A
sThe left side wave amplitude is lower than normally.
Hemorheology index: whole blood viscosity 3.94, plasma viscosity 1.29
2, draw so-and-so sex: man ages 71 address: ten li rivers of this city
Concise and to the point medical history: left limb dysfunction 6 months (once in city center hospital, because of the brain thromboembolism was in hospital 1 month)
Main symptom: lower limb hip joint: swing can translation 3 minutes, the lower limb toe joint: slightly moving 3 minutes,
Integration capability: can stand and take a step, need the people to take care of at any time 3 fens
Hemorheology index: whole blood viscosity value: shear rate (200): 5.23 shear rates (30): 6.76 shear rates (5): 11.15 shear rates (1): 23.86
After taking medicine 1 month: main symptom: the lower limb hip joint: refer to high more than 45 ℃ (1 minute).Lower limb toe joint: stretch and bend freely but weak (1 minute) integration capability of power: live on one's own life, simple work, and partial function (1 minute) is arranged
Hemorheology index: whole blood viscosity value: shear rate (200): 3.58 shear rates (30): 5.20 shear rates (5): 8.43 shear rates (1): 17.80
In sum, medicine of the present invention has been opened up the new way of treatment cerebrovascular disease, and have evident in efficacy, side effect is little, purity is high, taking convenience, advantage with low cost.
(4) specific embodiment
1. embodiment 1
Prescription: Folium Ginkgo 9kg Herba Ocimi (Herba Ocimi Pilosi) 13kg Radix et Rhizoma Rhei (stir-fried with wine) 9kg
Rhizoma Chuanxiong 12kg
Method for making:
Herba Ocimi (Herba Ocimi Pilosi), Rhizoma Chuanxiong are pulverized, added water, adopt steam distillation to extract volatile oil 4-6 hour, collect volatile oil.
Herba Ocimi (Herba Ocimi Pilosi), Rhizoma Chuanxiong extract the medicinal residues behind the volatile oil, decoct with water secondary, each 1-4 hour, merge decoction liquor.After concentrating, add ethanol and make and contain the alcohol amount and be 70-90%, place precipitation, filtration, collecting precipitation, filtrate recycling ethanol.
Folium Ginkgo, Radix et Rhizoma Rhei (stir-fried with wine) are pulverized, and add 60-90% ethanol extraction secondary, and each 1-4 hour, merge extractive liquid, filtered.
Again volatile oil, water extract-alcohol precipitation extract, ethanol extraction are mixed, altogether 4.2kg.Add 0.8kg starch again, after the mixing, drying incapsulates, and the 0.5g/ grain gets finished product.
Usage: one time three, three times on the one, boiled water is taken after mixing it with water.
2. embodiment 2
Prescription: Folium Ginkgo 12kg Herba Ocimi (Herba Ocimi Pilosi) 15kg Radix et Rhizoma Rhei (stir-fried with wine) 6kg
Rhizoma Chuanxiong 9kg Borneolum Syntheticum 0.2kg
Method for making is identical with embodiment 1, and volatile oil, water extract-alcohol precipitation extract and ethanol extraction make the Borneolum Syntheticum mix homogeneously after 4.5kg and the pulverizing altogether.Add 1kg amylum pregelatinisatum and microcrystalline Cellulose again, after the mixing, tabletting, the 0.3g/ sheet gets finished product.
Usage: one time five, three times on the one, boiled water is taken after mixing it with water.
3. embodiment 3
Prescription: Folium Ginkgo 10kg Herba Ocimi (Herba Ocimi Pilosi) 13kg Radix et Rhizoma Rhei (stir-fried with wine) 8kg
Rhizoma Chuanxiong 10kg
Method for making: volatile oil, water extract-alcohol precipitation extract and ethanol extraction are identical with embodiment 1, get extract 4kg.
Preparation behind the base of gel: it is 1-6% that Ka Baimujia water is made into concentration, placed 12-48 hour, and mixing, the hydro-oxidation sodium solution is transferred PH6-8, places 12-48 hour, adds the propylene glycol of 2-10%, the azone of 1-5%, mixing.
After the water extracting alcohol hypostasis added a spot of dissolve with ethanol, merge volatile oil and ethanol extraction, join in the base back for preparing, mix homogeneously, packing promptly gets the gel finished product.
Usage: with above-mentioned gel, clamp-on nasal cavity, each 0.2-0.3g, every day 4-6 time.4. embodiment 4
Prescription: Folium Ginkgo 11kg Herba Ocimi (Herba Ocimi Pilosi) 15kg Radix et Rhizoma Rhei (stir-fried with wine) 7kg
Rhizoma Chuanxiong 11kg
Method for making: identical with embodiment 1, volatile oil, water extract-alcohol precipitation extract and ethanol extraction make 5kg, add 1kg sucrose again, and the 1kg dextrin is made granule, pack, 7g/ bag.
Usage: one time one bag, a twice-daily, boiled water is taken after mixing it with water.
Claims (3)
1. medicine for the treatment of cerebrovascular disease is characterized in that: be to make by following weight proportion raw material and pharmaceutically acceptable auxiliaries,
Folium Ginkgo 9～12 Herba Ocimi (Herba Ocimi Pilosi)s 12～15 Radix et Rhizoma Rhei (stir-fried with wine) 6-9
Rhizoma Chuanxiong 9～12.
2. medicine for the treatment of cerebrovascular disease is characterized in that: be to make by following weight proportion raw material and pharmaceutically acceptable auxiliaries,
Folium Ginkgo 9～12 Herba Ocimi (Herba Ocimi Pilosi)s 12～15 Radix et Rhizoma Rhei (stir-fried with wine) 6-9
Rhizoma Chuanxiong 9～12 Borneolum Syntheticums 0.15～0.3.
3. according to the medicine of claim 1 or 2 described treatment cerebrovascular disease, it is characterized in that:
Above-mentioned medicine is made capsule, granule, tablet and gel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410003026 CN1232289C (en) | 2003-01-28 | 2004-01-11 | Medicine for treating cranial vascular disease |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03111838.0 | 2003-01-28 | ||
| CN03111838 | 2003-01-28 | ||
| CN 200410003026 CN1232289C (en) | 2003-01-28 | 2004-01-11 | Medicine for treating cranial vascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1513544A CN1513544A (en) | 2004-07-21 |
| CN1232289C true CN1232289C (en) | 2005-12-21 |
Family
ID=34276240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410003026 Expired - Lifetime CN1232289C (en) | 2003-01-28 | 2004-01-11 | Medicine for treating cranial vascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1232289C (en) |
-
2004
- 2004-01-11 CN CN 200410003026 patent/CN1232289C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1513544A (en) | 2004-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1748774A (en) | Brain tonifying preparation and new preparing method | |
| CN1775261A (en) | Mingmu-Dihuang preparation and new preparing method | |
| CN1748783A (en) | Dismenorrhea preparation and new preparing method | |
| CN1927279A (en) | Chinese medicine composition for treating skin disease | |
| CN1775246A (en) | Preparation for treating breast sore and new preparing method | |
| CN1298362C (en) | Compound Chinese medicine prepn for treating pulvic infection and its prepn process | |
| CN1748748A (en) | Little leaf deervetch herb preparation for pregnant woman and new preparing method | |
| CN1232289C (en) | Medicine for treating cranial vascular disease | |
| CN1850264A (en) | Safflower preparation for treating wound and new preparing method | |
| CN1879799A (en) | Menstruation-regulating preparation with asiabell and cassia bark and method for preparing same | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1544032A (en) | Anticancer Chinese traditional extracts and preparation process and application thereof | |
| CN1191849C (en) | Chinese medicine for treating breast disease | |
| CN1254267C (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN101032540A (en) | Medicine composition for curing arthritis and the preparing method and purpose thereof | |
| CN1857492A (en) | Qingxie preparation and its preparing process | |
| CN1824109A (en) | Liaoyuanqili medicinal preparation and its new preparation method | |
| CN1943694A (en) | A Chinese traditional medicinal composition for treating renal deficiency, edema, lumbago and gonalgia, etc. | |
| CN1530126A (en) | Medicine composition, preparing method and use for preparing gynacecopathia medicine | |
| CN1748741A (en) | Little leaf deervetch herb acne removing preparation and new preparing method | |
| CN1290551C (en) | A Chinese medicinal composition for invigorating kidney and strengthening bone | |
| CN1748775A (en) | Nujin preparation and new preparing method | |
| CN1246012C (en) | Medicine for treating endometriosis and its preparing process | |
| CN1824111A (en) | Cold dissipating network vessel quickening medicinal preparation and its new preparation method | |
| CN1281245C (en) | Medicine for treating asynodia and prospermia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG PROVINCE GERUN PHARMACEUTICAL CO.,LT Free format text: FORMER OWNER: SHANDONG CHINESE MEDICINE UNIV. ADDRESS Effective date: 20081121 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20081121 Address after: Nancha District Dongsheng Street in Yichun city of Heilongjiang Province, No. 2 Patentee after: HEILONGJIANG GERUN PHARMACEUTICAL CO.,LTD. Address before: No. ten, No. 53, Ji'nan, Shandong Patentee before: Shandong University of Traditional Chinese Medicine |
|
| ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG PROVINCE GERUN PHARMACEUTICAL CO.,LTD Free format text: FORMER OWNER: SHANDONG CHINESE MEDICINE UNIV. Effective date: 20081121 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170818 Address after: Yichun City, Heilongjiang province 153100 Nancha District Dongsheng Street No. 2 Patentee after: Yichun Wujia Ginseng Pharmaceutical Co.,Ltd. Address before: Yichun City, Heilongjiang province 153100 Nancha District Dongsheng Street No. 2 Patentee before: HEILONGJIANG GERUN PHARMACEUTICAL CO.,LTD. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20051221 |
|
| CX01 | Expiry of patent term |